Cellectis Sa Stock EBITDA

CLLS Stock

USD 1.87 0.01 0.54%

Cellectis SA fundamentals help investors to digest information that contributes to Cellectis' financial success or failures. It also enables traders to predict the movement of Cellectis Stock. The fundamental analysis module provides a way to measure Cellectis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cellectis stock.

		Last Reported	Projected for Next Year
	EBITDA	-98.1 M	-93.2 M

EBITDA is likely to gain to about (93.2 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cellectis SA Company EBITDA Analysis

Cellectis' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Cellectis EBITDA

(98.09 M)

Most of Cellectis' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cellectis SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Cellectis EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Cellectis is extremely important. It helps to project a fair market value of Cellectis Stock properly, considering its historical fundamentals such as EBITDA. Since Cellectis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cellectis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cellectis' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Net Receivables	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Intangible Assets	Current Deferred Revenue	Retained Earnings	Short Term Debt	Good Will	Net Tangible Assets	Long Term Debt	Long Term Investments	Short Long Term Debt	Treasury Stock	Property Plant Equipment	Short Term Investments	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.89	-0.72	0.33	0.34	0.94	-0.5	0.22	-0.46	0.12	-0.79	0.19	-0.64	0.93	0.44	0.5	-0.51	0.81	0.45	0.34	0.44	0.72	0.28	0.13	0.1
Total Stockholder Equity	0.89		-0.92	0.13	-0.1	0.94	-0.4	-0.01	-0.39	-0.11	-0.55	-0.21	-0.5	0.92	0.13	0.14	-0.73	0.67	0.06	0.1	0.04	0.4	0.57	0.48	-0.26
Net Debt	-0.72	-0.92		0.07	0.26	-0.91	0.41	0.28	0.4	-0.05	0.24	0.43	0.46	-0.84	0.09	0.17	0.82	-0.6	0.26	-0.12	0.23	-0.14	-0.64	-0.62	0.3
Net Receivables	0.33	0.13	0.07		0.43	0.14	-0.06	0.39	-0.01	0.13	-0.48	0.49	-0.39	0.17	0.2	0.45	0.0	0.38	0.52	0.0	0.41	0.47	-0.17	-0.29	0.33
Total Liab	0.34	-0.1	0.26	0.43		0.14	-0.31	0.38	-0.26	0.64	-0.58	0.88	-0.41	0.22	0.59	0.72	0.43	0.4	0.83	0.68	0.86	0.66	-0.58	-0.76	0.77
Total Current Assets	0.94	0.94	-0.91	0.14	0.14		-0.53	-0.05	-0.5	0.2	-0.57	-0.05	-0.63	0.97	0.21	0.21	-0.66	0.78	0.15	0.35	0.17	0.5	0.43	0.33	-0.01
Common Stock	-0.5	-0.4	0.41	-0.06	-0.31	-0.53		0.38	0.94	-0.34	0.5	-0.26	0.87	-0.57	-0.23	-0.36	0.31	-0.67	-0.34	-0.35	-0.34	-0.45	0.05	0.14	-0.17
Accounts Payable	0.22	-0.01	0.28	0.39	0.38	-0.05	0.38		0.46	-0.26	-0.44	0.32	0.15	-0.02	0.67	0.54	0.24	-0.05	0.51	-0.13	0.56	0.47	-0.05	-0.17	0.11
Intangible Assets	-0.46	-0.39	0.4	-0.01	-0.26	-0.5	0.94	0.46		-0.35	0.46	-0.26	0.76	-0.54	-0.23	-0.36	0.28	-0.64	-0.34	-0.36	-0.34	-0.44	0.07	0.16	-0.19
Current Deferred Revenue	0.12	-0.11	-0.05	0.13	0.64	0.2	-0.34	-0.26	-0.35		-0.01	0.43	-0.4	0.19	0.05	0.08	0.16	0.34	0.2	0.78	0.28	0.17	-0.41	-0.45	0.7
Retained Earnings	-0.79	-0.55	0.24	-0.48	-0.58	-0.57	0.5	-0.44	0.46	-0.01		-0.58	0.6	-0.68	-0.65	-0.81	0.12	-0.63	-0.83	-0.32	-0.79	-0.89	0.07	0.3	-0.27
Short Term Debt	0.19	-0.21	0.43	0.49	0.88	-0.05	-0.26	0.32	-0.26	0.43	-0.58		-0.33	0.07	0.48	0.8	0.61	0.3	0.87	0.51	0.85	0.66	-0.74	-0.91	0.72
Good Will	-0.64	-0.5	0.46	-0.39	-0.41	-0.63	0.87	0.15	0.76	-0.4	0.6	-0.33		-0.67	-0.28	-0.43	0.36	-0.79	-0.41	-0.43	-0.41	-0.54	0.07	0.18	-0.22
Net Tangible Assets	0.93	0.92	-0.84	0.17	0.22	0.97	-0.57	-0.02	-0.54	0.19	-0.68	0.07	-0.67		0.22	0.27	-0.57	0.77	0.27	0.39	0.27	0.55	0.39	0.22	-0.02
Long Term Debt	0.44	0.13	0.09	0.2	0.59	0.21	-0.23	0.67	-0.23	0.05	-0.65	0.48	-0.28	0.22		0.8	0.16	0.3	0.72	0.24	0.84	0.73	-0.23	-0.34	0.37
Long Term Investments	0.5	0.14	0.17	0.45	0.72	0.21	-0.36	0.54	-0.36	0.08	-0.81	0.8	-0.43	0.27	0.8		0.3	0.47	0.91	0.3	0.92	0.9	-0.48	-0.62	0.53
Short Long Term Debt	-0.51	-0.73	0.82	0.0	0.43	-0.66	0.31	0.24	0.28	0.16	0.12	0.61	0.36	-0.57	0.16	0.3		-0.47	0.35	0.2	0.37	0.05	-0.7	-0.71	0.52
Treasury Stock	0.81	0.67	-0.6	0.38	0.4	0.78	-0.67	-0.05	-0.64	0.34	-0.63	0.3	-0.79	0.77	0.3	0.47	-0.47		0.41	0.37	0.41	0.55	0.0	-0.11	0.14
Property Plant Equipment	0.45	0.06	0.26	0.52	0.83	0.15	-0.34	0.51	-0.34	0.2	-0.83	0.87	-0.41	0.27	0.72	0.91	0.35	0.41		0.41	0.96	0.81	-0.46	-0.69	0.53
Short Term Investments	0.34	0.1	-0.12	0.0	0.68	0.35	-0.35	-0.13	-0.36	0.78	-0.32	0.51	-0.43	0.39	0.24	0.3	0.2	0.37	0.41		0.46	0.36	-0.45	-0.52	0.67
Long Term Debt Total	0.44	0.04	0.23	0.41	0.86	0.17	-0.34	0.56	-0.34	0.28	-0.79	0.85	-0.41	0.27	0.84	0.92	0.37	0.41	0.96	0.46		0.83	-0.49	-0.69	0.58
Capital Surpluse	0.72	0.4	-0.14	0.47	0.66	0.5	-0.45	0.47	-0.44	0.17	-0.89	0.66	-0.54	0.55	0.73	0.9	0.05	0.55	0.81	0.36	0.83		-0.21	-0.37	0.54
Net Invested Capital	0.28	0.57	-0.64	-0.17	-0.58	0.43	0.05	-0.05	0.07	-0.41	0.07	-0.74	0.07	0.39	-0.23	-0.48	-0.7	0.0	-0.46	-0.45	-0.49	-0.21		0.93	-0.69
Net Working Capital	0.13	0.48	-0.62	-0.29	-0.76	0.33	0.14	-0.17	0.16	-0.45	0.3	-0.91	0.18	0.22	-0.34	-0.62	-0.71	-0.11	-0.69	-0.52	-0.69	-0.37	0.93		-0.69
Capital Stock	0.1	-0.26	0.3	0.33	0.77	-0.01	-0.17	0.11	-0.19	0.7	-0.27	0.72	-0.22	-0.02	0.37	0.53	0.52	0.14	0.53	0.67	0.58	0.54	-0.69	-0.69

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Cellectis

Ebitda Over Time

Cellectis Ebitda

Ebitda

(93.19 Million)

At this time, Cellectis' EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Cellectis SA reported earnings before interest,tax, depreciation and amortization of (98.09 Million). This is 111.18% lower than that of the Biotechnology sector and 197.94% lower than that of the Health Care industry. The ebitda for all United States stocks is 102.52% higher than that of the company.

Cellectis EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellectis' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cellectis could also be used in its relative valuation, which is a method of valuing Cellectis by comparing valuation metrics of similar companies.

Cellectis is currently under evaluation in ebitda category among its peers.

Cellectis Current Valuation Drivers

We derive many important indicators used in calculating different scores of Cellectis from analyzing Cellectis' financial statements. These drivers represent accounts that assess Cellectis' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cellectis' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	745.4M	1.3B	379.2M	96.8M	160.4M	152.3M
Enterprise Value	432.1M	1.1B	295.3M	82.0M	108.7M	103.3M

Cellectis Institutional Holders

Institutional Holdings refers to the ownership stake in Cellectis that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cellectis' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cellectis' value.

		Shares
First Affirmative Financial Network	2024-09-30	21.1 K
Bnp Paribas Arbitrage, Sa	2024-06-30	16.7 K
Baird Financial Group, Inc.	2024-09-30	15.1 K
Xtx Topco Ltd	2024-09-30	13.1 K
Wells Fargo & Co	2024-06-30	12.8 K
Geode Capital Management, Llc	2024-09-30	10.8 K
Harbour Investments, Inc.	2024-09-30	6.1 K
Rhumbline Advisers	2024-06-30	3.9 K
Blackrock Inc	2024-06-30	2.8 K
Long Focus Capital Management, Llc	2024-09-30	4.6 M
Capital Research & Mgmt Co - Division 3	2024-09-30	1.8 M

Cellectis Fundamentals

	Return On Equity	-0.82
	Return On Asset	-0.16
	Profit Margin	(2.34) %
	Operating Margin	(0.60) %
	Current Valuation	11.48 M
	Shares Outstanding	100.09 M
	Shares Owned By Insiders	3.86 %
	Shares Owned By Institutions	14.60 %
	Number Of Shares Shorted	156.19 K
	Price To Earning	(14.84) X
	Price To Book	1.45 X
	Price To Sales	5.19 X
	Revenue	755 K
	Gross Profit	23.95 M
	EBITDA	(98.09 M)
	Net Income	(116.83 M)
	Cash And Equivalents	153.13 M
	Cash Per Share	3.37 X
	Total Debt	92.85 M
	Debt To Equity	0.52 %
	Current Ratio	3.17 X
	Book Value Per Share	1.29 X
	Cash Flow From Operations	(24.75 M)
	Short Ratio	3.28 X
	Earnings Per Share	(1.16) X
	Target Price	6.5
	Number Of Employees	216
	Beta	3.2
	Market Capitalization	187.18 M
	Total Asset	334.27 M
	Retained Earnings	(405.76 M)
	Working Capital	77.86 M
	Current Asset	51 M
	Current Liabilities	26.28 M
	Net Asset	334.27 M

About Cellectis Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cellectis SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectis SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Cellectis Stock Analysis

When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC